261 related articles for article (PubMed ID: 10951397)
41. RET oncogene expression of papillary thyroid carcinoma in Korea.
Chung KW; Chang MC; Noh DY; Oh SK; Choe KJ; Youn YK
Surg Today; 2004; 34(6):485-92. PubMed ID: 15170542
[TBL] [Abstract][Full Text] [Related]
42. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy.
Nakashima M; Takamura N; Namba H; Saenko V; Meirmanov S; Matsumoto N; Hayashi T; Maeda S; Sekine I
Hum Pathol; 2007 Apr; 38(4):621-8. PubMed ID: 17270245
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
44. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells.
Ameziane-El-Hassani R; Boufraqech M; Lagente-Chevallier O; Weyemi U; Talbot M; Métivier D; Courtin F; Bidart JM; El Mzibri M; Schlumberger M; Dupuy C
Cancer Res; 2010 May; 70(10):4123-32. PubMed ID: 20424115
[TBL] [Abstract][Full Text] [Related]
45. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
46. Molecular basis off hurthle cell papillary thyroid carcinoma.
Cheung CC; Ezzat S; Ramyar L; Freeman JL; Asa SL
J Clin Endocrinol Metab; 2000 Feb; 85(2):878-82. PubMed ID: 10690905
[TBL] [Abstract][Full Text] [Related]
47. RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.
Nibu K; Otsuki N; Nakao K; Sugasawa M; Rothstein JL
Eur Arch Otorhinolaryngol; 2005 May; 262(5):368-73. PubMed ID: 15368067
[TBL] [Abstract][Full Text] [Related]
48. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
[TBL] [Abstract][Full Text] [Related]
49. Real-time quantitative analysis of E-cadherin expression in ret/PTC-1-activated thyroid neoplasms.
Smyth P; Sheils O; Finn S; Martin C; O'Leary J; Sweeney EC
Int J Surg Pathol; 2001 Oct; 9(4):265-72. PubMed ID: 12574841
[TBL] [Abstract][Full Text] [Related]
50. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?
Sugg SL; Zheng L; Rosen IB; Freeman JL; Ezzat S; Asa SL
J Clin Endocrinol Metab; 1996 Sep; 81(9):3360-5. PubMed ID: 8784097
[TBL] [Abstract][Full Text] [Related]
51. [Gene rearrangement analysis of papillary thyroid carcinoma].
Wang YL; Wang JC; Li DS; Zhu YX; Wu Y; Ji QH
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Dec; 42(12):929-33. PubMed ID: 18335752
[TBL] [Abstract][Full Text] [Related]
52. [Oncogenes RET/PTC and mechanisms of their involvement in thyroid cancerogenesis].
Voskoboĭnyk LH
Ukr Biokhim Zh (1999); 2009; 81(6):17-25. PubMed ID: 20387655
[TBL] [Abstract][Full Text] [Related]
53. Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears.
Ferraz C; Rehfeld C; Krogdahl A; Precht Jensen EM; Bösenberg E; Narz F; Hegedüs L; Paschke R; Eszlinger M
Thyroid; 2012 Oct; 22(10):1025-30. PubMed ID: 23025542
[TBL] [Abstract][Full Text] [Related]
54. Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood.
Sadetzki S; Calderon-Margalit R; Modan B; Srivastava S; Tuttle RM
J Clin Endocrinol Metab; 2004 May; 89(5):2281-9. PubMed ID: 15126554
[TBL] [Abstract][Full Text] [Related]
55. Simultaneous occurrence of PAX8-PPARg and RET-PTC3 rearrangements in a follicular variant of papillary thyroid carcinoma.
Caria P; Dettori T; Frau DV; Di Oto E; Morandi L; Parmeggiani A; Tallini G; Vanni R
Am J Surg Pathol; 2012 Sep; 36(9):1415-20. PubMed ID: 22895275
[TBL] [Abstract][Full Text] [Related]
56. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
[TBL] [Abstract][Full Text] [Related]
57. Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis.
Giannini R; Salvatore G; Monaco C; Sferratore F; Pollina L; Pacini F; Basolo F; Fusco A; Santoro M
Int J Oncol; 2000 Mar; 16(3):485-9. PubMed ID: 10675479
[TBL] [Abstract][Full Text] [Related]
58. RET/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation.
Nakazawa T; Murata S; Kondo T; Niu D; Mochizuki K; Kawasaki T; Yamane T; Nakamura N; Katoh R
Virchows Arch; 2009 Jul; 455(1):35-41. PubMed ID: 19495791
[TBL] [Abstract][Full Text] [Related]
59. Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma.
Finn SP; Smyth P; O'Leary J; Sweeney EC; Sheils O
J Clin Endocrinol Metab; 2003 Feb; 88(2):938-41. PubMed ID: 12574236
[TBL] [Abstract][Full Text] [Related]
60. RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas.
de Vries MM; Celestino R; Castro P; Eloy C; Máximo V; van der Wal JE; Plukker JT; Links TP; Hofstra RM; Sobrinho-Simões M; Soares P
Histopathology; 2012 Nov; 61(5):833-43. PubMed ID: 22803838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
